

DOCKET: CU-2560

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: John P. McKEARN et al )

SERIAL NO: 09/857,995 )

) Group Art Unit:

) 1614

FILING DATE: October 5, 2001 )

TITLE: METHOD OF USING A MATRIX METALLOPROTEINASE )  
INHIBITOR AND ONE OR MORE ANTINEOPLASTIC )  
AGENTS AS A COMBINATION THERAPY IN THE )  
TREATMENT OF NEOPLASIA )The Commissioner for Patents  
Washington, D.C. 20231**RECEIVED**  
MAR 04 2002  
TECH CENTER 1600/2900REQUEST FOR CORRECTED FILING RECEIPT

Dear Sir:

The official filing receipt has been received from the Patent Office in the above application.


There are several errors therein as shown on the attached copy, and as follows:

1. The state of residence of the fifth inventor (Alane T. Koki) is incorrect as the state of residence should be Missouri (MO).
4. The serial number of the U.S. provisional application is incorrect.

Reference is made to the Combined Declaration & Power of Attorney, which was filed on October 5, 2001.

It is believed that no fee is due since the correction is not due to any error by the applicant and issuance of a corrected filing receipt is respectfully requested.

Respectfully submitted,



Attorney for Applicant

February 7, 2002

Date

17

Richard J. Strell, Reg. 25765  
c/o Ladas & Parry  
221 South Michigan Avenue  
Chicago, Illinois 60604  
(312) 421-1300



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/857,995	10/05/2001	1614	2520	CU-2560 RJS		106	3

CONFIRMATION NO. 4037

## FILING RECEIPT



\*OC000000007277846\*

Richard J Streit  
Ladas & Parry  
Suite 1200  
224 South Michigan Avenue  
Chicago, IL 60604

RECEIVED  
MAR 04 2002  
TECH CENTER 1600/2900

Date Mailed: 01/08/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

✓  
John P. McKearn, Glencoe, MO;  
Gary Gordon, Highland, IL;  
James J. Cunningham, Chicago, IL;  
Stephen T. Gately, Palatine, IL;  
Alane T. Koki, Beaufort, MT; MO (Missouri)  
Jaime L. Masferrer, Ballwin, MO;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/30699 12/22/1999

## Foreign Applications

UNITED STATES OF AMERICA 60113786 12/23/1998

60113786

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

Title

Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

LAW OFFICES

**LADAS & PARRY**

JCTO Rec'd PCT/PTO 07 FEB 2002 3/16/2

224 South Michigan Avenue • Chicago, Illinois 60604, U.S.A.

Telephone: (312) 427-1300

Telefax: (312) 427-6663 (312) 427-6668

*THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE. If the reader of this message is not the intended recipient or an employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us by mail. Thank you.*

LENGTH OF TRANSMISSION (INCLUSIVE OF THIS SHEET): 4 page(s)**DATE:** February 7, 2002**FROM:** Richard J. Streit/ds**TO:** Commissioner for Patents  
Washington, D.C. 20231

Fax No. 703-308-7751

**RE:** John P. McKearn et al  
U.S. Serial No. 09/857,995  
Filed October 5, 2001  
METHOD OF USING A MATRIX METALLOPROTEINASE  
INHIBITOR AND ONE OR MORE ANTINEOPLASTIC  
AGENTS AS A COMBINATION THERAPY IN THE  
TREATMENT OF NEOPLASIA  
Docket: CU-2560

**REMARKS:**

Attached Is a Request for Corrected Filing Receipt

**RECEIVED**

MAR 04 2002

TECH CENTER 1600/2900